154 related articles for article (PubMed ID: 21793839)
1. Metabolic approaches to overcoming chemoresistance in ovarian cancer.
Suh DH; Kim MK; No JH; Chung HH; Song YS
Ann N Y Acad Sci; 2011 Jul; 1229():53-60. PubMed ID: 21793839
[TBL] [Abstract][Full Text] [Related]
2. [Chemoresistance in ovarian cancer. State of the art and future prospects].
Katsaros D; Fracchioli S; Arese P; Enria R; Cassinelli P; Mingrone K; Piccinno R; Rigault de la Longrais IA; Massobrio M
Minerva Ginecol; 1999 Dec; 51(12):483-99. PubMed ID: 10767997
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of HIPK2 circumvents the blockade of apoptosis in chemoresistant ovarian cancer cells.
Puca R; Nardinocchi L; Pistritto G; D'Orazi G
Gynecol Oncol; 2008 Jun; 109(3):403-10. PubMed ID: 18395248
[TBL] [Abstract][Full Text] [Related]
4. Akt-mediated cisplatin resistance in ovarian cancer: modulation of p53 action on caspase-dependent mitochondrial death pathway.
Yang X; Fraser M; Moll UM; Basak A; Tsang BK
Cancer Res; 2006 Mar; 66(6):3126-36. PubMed ID: 16540663
[TBL] [Abstract][Full Text] [Related]
5. Oncolytic herpes simplex virus-1 lacking ICP34.5 induces p53-independent death and is efficacious against chemotherapy-resistant ovarian cancer.
Coukos G; Makrigiannakis A; Kang EH; Rubin SC; Albelda SM; Molnar-Kimber KL
Clin Cancer Res; 2000 Aug; 6(8):3342-53. PubMed ID: 10955822
[TBL] [Abstract][Full Text] [Related]
6. Gene expression profiling of paired ovarian tumors obtained prior to and following adjuvant chemotherapy: molecular signatures of chemoresistant tumors.
L'Espérance S; Popa I; Bachvarova M; Plante M; Patten N; Wu L; Têtu B; Bachvarov D
Int J Oncol; 2006 Jul; 29(1):5-24. PubMed ID: 16773180
[TBL] [Abstract][Full Text] [Related]
7. Metabolic orchestration between cancer cells and tumor microenvironment as a co-evolutionary source of chemoresistance in ovarian cancer: a therapeutic implication.
Suh DH; Kim HS; Kim B; Song YS
Biochem Pharmacol; 2014 Nov; 92(1):43-54. PubMed ID: 25168677
[TBL] [Abstract][Full Text] [Related]
8. Critical evaluation of p53 as a prognostic marker in ovarian cancer.
Hall J; Paul J; Brown R
Expert Rev Mol Med; 2004 May; 6(12):1-20. PubMed ID: 15147608
[TBL] [Abstract][Full Text] [Related]
9. Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells.
Wang Y; Niu XL; Qu Y; Wu J; Zhu YQ; Sun WJ; Li LZ
Cancer Lett; 2010 Sep; 295(1):110-23. PubMed ID: 20236757
[TBL] [Abstract][Full Text] [Related]
10. Cisplatin induces p53-dependent FLICE-like inhibitory protein ubiquitination in ovarian cancer cells.
Abedini MR; Muller EJ; Brun J; Bergeron R; Gray DA; Tsang BK
Cancer Res; 2008 Jun; 68(12):4511-7. PubMed ID: 18559494
[TBL] [Abstract][Full Text] [Related]
11. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy.
Judson PL; Watson JM; Gehrig PA; Fowler WC; Haskill JS
Cancer Res; 1999 May; 59(10):2425-32. PubMed ID: 10344753
[TBL] [Abstract][Full Text] [Related]
12. Caspase 9 is required for p53-dependent apoptosis and chemosensitivity in a human ovarian cancer cell line.
Wu GS; Ding Z
Oncogene; 2002 Jan; 21(1):1-8. PubMed ID: 11791171
[TBL] [Abstract][Full Text] [Related]
13. p53 mutations in epithelial ovarian cancers: possible role in predicting chemoresistance.
Laframboise S; Chapman W; McLaughlin J; Andrulis IL
Cancer J; 2000; 6(5):302-8. PubMed ID: 11079169
[TBL] [Abstract][Full Text] [Related]
14. Overcoming TRAIL resistance in ovarian carcinoma.
Bevis KS; Buchsbaum DJ; Straughn JM
Gynecol Oncol; 2010 Oct; 119(1):157-63. PubMed ID: 20638107
[TBL] [Abstract][Full Text] [Related]
15. Sensitization of cis-platinum by a recombinant adenovirus vector expressing wild-type p53 gene in human ovarian carcinomas.
Song K; Li Z; Seth P; Cowan KH; Sinha BK
Oncol Res; 1997; 9(11-12):603-9. PubMed ID: 9563008
[TBL] [Abstract][Full Text] [Related]
16. Cooperative effect of adenoviral p53 gene therapy and standard chemotherapy in ovarian cancer cells independent of the endogenous p53 status.
Quist SR; Wang-Gohrke S; Köhler T; Kreienberg R; Runnebaum IB
Cancer Gene Ther; 2004 Aug; 11(8):547-54. PubMed ID: 15153938
[TBL] [Abstract][Full Text] [Related]
17. Overcoming apoptosis deficiency of melanoma-hope for new therapeutic approaches.
Eberle J; Kurbanov BM; Hossini AM; Trefzer U; Fecker LF
Drug Resist Updat; 2007 Dec; 10(6):218-34. PubMed ID: 18054518
[TBL] [Abstract][Full Text] [Related]
18. Apoptotic effect of celecoxib dependent upon p53 status in human ovarian cancer cells.
Song YC; Kim SH; Juhnn YS; Song YS
Ann N Y Acad Sci; 2007 Jan; 1095():26-34. PubMed ID: 17404014
[TBL] [Abstract][Full Text] [Related]
19. Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer.
Reles A; Wen WH; Schmider A; Gee C; Runnebaum IB; Kilian U; Jones LA; El-Naggar A; Minguillon C; Schönborn I; Reich O; Kreienberg R; Lichtenegger W; Press MF
Clin Cancer Res; 2001 Oct; 7(10):2984-97. PubMed ID: 11595686
[TBL] [Abstract][Full Text] [Related]
20. Curcumin-induced apoptosis in ovarian carcinoma cells is p53-independent and involves p38 mitogen-activated protein kinase activation and downregulation of Bcl-2 and survivin expression and Akt signaling.
Watson JL; Greenshields A; Hill R; Hilchie A; Lee PW; Giacomantonio CA; Hoskin DW
Mol Carcinog; 2010 Jan; 49(1):13-24. PubMed ID: 19676105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
